Geron Corporation
Geron Corporation is a Late Stage Clinical Biopharmaceutical company focused on the development and potential commercialization of a first in class telomerase inhibitor, imetelstat, an innovative therapeutic for hematologic myeloid malignancies. The headquarters is in USA.
Geron Corporation Annual Total Revenue for year ending Dec-2022 was 0.5 million USD and and Net loss for year ending Dec-2022 was -141 million USD.
Geron Corporation Annual Total Revenue for year ending Dec-2021 was 1.3 million USD and and Net loss for year ending Dec-2021 was =116 million USD.
As on 2022, Geron Corporation has 107 employees.